Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Hematologic Malignancies Resource Center

Featured

News
Real-World Treatment Discontinuation Among Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Lower Adherence to Ibrutinib Among Real-World Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
Quiz
Quiz: HCRU and Costs With CAR-T Therapy vs Transplantation for DLCBL
04/08/2021
04/08/2021
Journal of Clinical Pathways
FDA Approves Crizotinib for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
Interview
FDA Approves Crizotinib for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
03/19/2021
03/19/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for B-Cell Lymphomas
NCCN Updates Clinical Practice Guideline for B-Cell Lymphomas
03/17/2021

Janelle Bradley

Janelle Bradley
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive...
03/17/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL
03/16/2021
03/16/2021
Journal of Clinical Pathways
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
Videos
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
Videos
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
12/09/2020
12/09/2020
Journal of Clinical Pathways
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways

News

News
Real-World Treatment Discontinuation Among Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Lower Adherence to Ibrutinib Among Real-World Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL
03/16/2021
03/16/2021
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
Outcomes of CAR-T vs Alternate Therapies for DLBCL in the Real-World Setting
10/22/2020
10/22/2020
Journal of Clinical Pathways
News
New Standard Treatment Approach for Patients With DLBCL
10/17/2020
10/17/2020
Journal of Clinical Pathways
News
Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM
10/15/2020
Findings from a recent study demonstrate that Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with WM and a preferable option for use in previously treated patients.
Findings from a recent study demonstrate that Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with WM and a preferable option for use in previously treated patients.
Findings from a recent study...
10/15/2020
Journal of Clinical Pathways
News
Reducing Cause-Specific Mortality in Classical Hodgkin Lymphoma
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
Real-World Costs of Azacitidine Treatment in Patients With AML
09/28/2020
09/28/2020
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
News
FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
Patient-Reported Outcomes Show Comparable Quality of Life in Pembrolizumab Plus CCRT for High-Risk, Locally Advanced Cervical Cancer
03/20/2024

Brandon Twyford

Brandon Twyford
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the...
03/20/2024
Journal of Clinical Pathways
News
ChatGPT Vs Multidisciplinary Tumor Board: Treatment Recommendations for Patients With Gynecologic Cancers
03/19/2024

Grace Taylor

Grace Taylor
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and...
03/19/2024
Journal of Clinical Pathways

Guideline Updates

Guideline Updates
NCCN Updates Clinical Practice Guidelines for Multiple Myeloma
01/11/2023

Yvette C. Terrie

Yvette C. Terrie
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published...
01/11/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guidelines in Thyroid Carcinoma
09/08/2022

Yvette C Terrie

Yvette C Terrie
The National Comprehensive Cancer Network recently published updated recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, along with surgical management of differentiated thyroid carcinoma.
The National Comprehensive Cancer Network recently published updated recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, along with surgical management of differentiated thyroid carcinoma.
The National Comprehensive...
09/08/2022
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022

Yvette C Terrie

Yvette C Terrie
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guidelines for CLL/SLL
01/24/2022

Janelle Bradley

Janelle Bradley
On January 18, 2022, the NCCN updated their Clinical Practice Guidelines for CLL/SLL, recommending zanubrutinib as a category 2A preferred regimen for the first-line treatment of patients with CLL/SLL without del(17p)/TP53 mutations.
On January 18, 2022, the NCCN updated their Clinical Practice Guidelines for CLL/SLL, recommending zanubrutinib as a category 2A preferred regimen for the first-line treatment of patients with CLL/SLL without del(17p)/TP53 mutations.
On January 18, 2022, the NCCN...
01/24/2022
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Small Cell Lung Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Small Cell Lung Cancer
03/24/2021

Janelle Bradley

Janelle Bradley
NCCN released an update to its clinical practice guideline for small cell lung cancer, featuring modifications for supportive care and subsequent systemic therapy.
NCCN released an update to its clinical practice guideline for small cell lung cancer, featuring modifications for supportive care and subsequent systemic therapy.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
03/24/2021

Janelle Bradley

Janelle Bradley
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021

Janelle Bradley

Janelle Bradley
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/10/2021
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National...
03/10/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guidelines for CLL/SLL
Guideline Updates
NCCN Updates Clinical Practice Guidelines for CLL/SLL
12/14/2020
12/14/2020
Journal of Clinical Pathways
ASCO Updates Guideline on Early Breast Cancer Treatment
Guideline Updates
ASCO Updates Guideline on Early Breast Cancer Treatment
11/18/2020
11/18/2020
Journal of Clinical Pathways

Interviews

FDA Approves Crizotinib for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
Interview
FDA Approves Crizotinib for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
03/19/2021
03/19/2021
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Interview
Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers
03/27/2024
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the...
03/27/2024
Journal of Clinical Pathways
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
James Hamrick, MD, MPH
Interview
Improving Patient Care Through AI Clinical Decision Support Tools
03/21/2023
James Hamrick, MD, MPH, discusses the ways in which incorporating AI into cancer care can improve the timeliness of care for patients, nudge providers to use novel therapies in practice, and reduce inequities in health care.
James Hamrick, MD, MPH, discusses the ways in which incorporating AI into cancer care can improve the timeliness of care for patients, nudge providers to use novel therapies in practice, and reduce inequities in health care.
James Hamrick, MD, MPH,...
03/21/2023
Journal of Clinical Pathways
Rebecca Maniago, PharmdD, BCOP
Interview
The Value of AI-Enabled Clinical Decision Support Tools in Clinical Pathways
03/20/2023
Rebecca Maniago, PharmD, BCOP, discusses the impact that AI-enabled clinical decision support will have on clinical pathways, as well as the ways in which technology is playing a large role in the current landscape of oncology care.
Rebecca Maniago, PharmD, BCOP, discusses the impact that AI-enabled clinical decision support will have on clinical pathways, as well as the ways in which technology is playing a large role in the current landscape of oncology care.
Rebecca Maniago, PharmD, BCOP,...
03/20/2023
Journal of Clinical Pathways
HER2-Low Breast Cancer
Anne Hubbard, MBA
Interview
Utilizing Episodic Payments to Improve Access and Quality in Cancer Care
11/15/2022
Anne Hubbard, MBA, Director of Health Policy, American Society for Radiation Oncology, discusses the Radiation Oncology Model, which may pave a path for use of an episode-based payment concept in the broader realm of cancer care.
Anne Hubbard, MBA, Director of Health Policy, American Society for Radiation Oncology, discusses the Radiation Oncology Model, which may pave a path for use of an episode-based payment concept in the broader realm of cancer care.
Anne Hubbard, MBA, Director of...
11/15/2022
Journal of Clinical Pathways
Lee Fleisher, MD
Interview
CMS National Quality Strategy Focuses on Quality, Safety, Affordability Standards in Oncology Care
11/10/2022
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the...
11/10/2022
Journal of Clinical Pathways

Blogs

Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Kendall Logan, MPH.
Quality Outlook
A Tale of Two States: Examining the Best and Worst Performing States for HPV Vaccination
02/12/2024

Kendall Logan, MPH; Anne DiSalvo, MPH, MBA; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Kendall Logan, MPH; Anne DiSalvo, MPH...
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a...
02/12/2024
Journal of Clinical Pathways
Theresa Schmidt headshot.
Quality Outlook
2024 Quality Outlook Revealed: Insights from 2023 Fall Conferences
02/02/2024

Theresa Schmidt, MA; Danny Bellet, MBA; Donna Dugan, PhD, MS; Erik Muther; David Sloan, PhD; Tom Valuck, MD, JD

Theresa Schmidt, MA; Danny Bellet, MB...
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the...
02/02/2024
Journal of Clinical Pathways
Anne Disalvo headshot
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Racial and Ethnic Disparities in HPV Vaccination
11/10/2023

Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Anne DiSalvo, MPH, MBA; Kendall Logan...
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a...
11/10/2023
Journal of Clinical Pathways
Anne DiSalvo.
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Geographic Disparities in HPV Vaccination
10/03/2023

Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Anne DiSalvo, MPH, MBA; Kendall Logan...
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part...
10/03/2023
Journal of Clinical Pathways
David Blaisdell, BA, Real Chemistry.
Quality Outlook
Enhancing Value-Based Oncology Care: What Has CMMI Learned From the OCM?
09/22/2023

David Blaisdell; Blog Editor: Tom Valuck, MD, JD

David Blaisdell; Blog Editor: Tom Val...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about...
09/22/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023

Jacqlyn Riposo, MBA; Tom Valuck, MD, JD

Jacqlyn Riposo, MBA; Tom Valuck, MD, ...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Winston Wong
Editor Insights
A Look Back at Clinical Pathways in 2022
02/21/2023
Winston Wong, PharmD, Editor-in-Chief
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal...
02/21/2023
Journal of Clinical Pathways
Sarena Ho, MSPH
Quality Outlook
Quality Measures for Medicare’s Enhancing Oncology Model (EOM): New and Improved or More of the Same?
01/26/2023

David Blaisdell; Sarena Ho, MSPH; Tom Valuck, MD, JD

David Blaisdell; Sarena Ho, MSPH; Tom...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center...
01/26/2023
Journal of Clinical Pathways
Nina Regenold, MSc
Quality Outlook
The Oncology-Oral Health Value Bridge: Put Your Money Where Your Mouth Is
08/18/2022

Nina Regenold, MSc; Kaitlyn Esselman, MHS; David Blaisdell; Eva Lenoir, MPH; and Tom Valuck, MD, JD

Nina Regenold, MSc; Kaitlyn Esselman,...
Nina Regenold, MSc, and colleagues highlight the need for payers and providers to include oral health in the development of value-based models in oncology care, arguing that doing so could lead to improved patient outcomes and lower costs of...
Nina Regenold, MSc, and colleagues highlight the need for payers and providers to include oral health in the development of value-based models in oncology care, arguing that doing so could lead to improved patient outcomes and lower costs of...
Nina Regenold, MSc, and...
08/18/2022
Journal of Clinical Pathways

Videos

Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
Videos
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
Videos
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
12/09/2020
12/09/2020
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways
Anna Halpern, MD
Videos
An Overview of the Benefits and Challenges of Providing Outpatient Oncology Care
04/06/2024

Featuring Anna Halpern, MD

Featuring Anna Halpern, MD
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her...
04/06/2024
Journal of Clinical Pathways
Ted Okon, MBA
Videos
Oncology Legislative Updates and Predictions From Capitol Hill: COA 2024
04/05/2024

Featuring Ted Okon, MBA

Featuring Ted Okon, MBA
Ted Okon, MBA, discusses some of the latest pressing issues in Washington that are impacting oncology stakeholders, particularly in the community oncology setting.
Ted Okon, MBA, discusses some of the latest pressing issues in Washington that are impacting oncology stakeholders, particularly in the community oncology setting.
Ted Okon, MBA, discusses some of...
04/05/2024
Journal of Clinical Pathways

Podcasts

Bonus Episode: Updates From the EHA Annual Congress
Bonus
Bonus Episode: Updates From the EHA Annual Congress
06/26/2020

Graham Collins, David Steensma, and Vincent Rajkumar

Graham Collins, David Steensma, and V...
Chadi checks in with Graham Collins, David Steensma, and Vincent Rajkumar to discuss the most prevalent and noteworthy clinical research from the EHA meeting for Hodgkin lymphoma, MDS and AML, multiple myeloma, and DLBCL.
Chadi checks in with Graham Collins, David Steensma, and Vincent Rajkumar to discuss the most prevalent and noteworthy clinical research from the EHA meeting for Hodgkin lymphoma, MDS and AML, multiple myeloma, and DLBCL.
Chadi checks in with Graham...
06/26/2020
Journal of Clinical Pathways
Podcasts
Episode 6: Rapid Scientific Advancements in Value-Based Arrangements: Why Are Pathways Important?
06/29/2023

Featuring Gordon Kuntz and Aimee Ginsburg, PharmD

Featuring Gordon Kuntz and Aimee Gins...
On episode 6 of Oncology Innovations, host Gordon Kuntz sits down with Aimee Ginsburg, PharmD, McKesson Value Pathways, to discuss the value of clinical pathways in a world of rapidly advancing scientific data, and how decision support tools...
On episode 6 of Oncology Innovations, host Gordon Kuntz sits down with Aimee Ginsburg, PharmD, McKesson Value Pathways, to discuss the value of clinical pathways in a world of rapidly advancing scientific data, and how decision support tools...
On episode 6 of Oncology...
06/29/2023
Journal of Clinical Pathways
Podcasts
Cancer Genomics and Genetic Testing in the Era of Precision Medicine: What is a Precision Model of Care?
12/05/2022

An interview with Dan Rhodes, CEO, Strata Oncology

An interview with Dan Rhodes, CEO, St...
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes,...
12/05/2022
Journal of Clinical Pathways
Dan Rhodes, PhD
Podcasts
Episode 5: Cancer Genomics and Genetic Testing in the Era of Precision Medicine: What is a Precision Model of Care?
10/31/2022
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes,...
10/31/2022
Journal of Clinical Pathways
Podcasts
The Value and Opportunity in Individualized Cancer Care: Part 1
09/08/2022

An interview with Bryan Loy, MD, MBA, and Tushar Pandey, MBA, CEO

An interview with Bryan Loy, MD, MBA,...
Gordon Kuntz; Bryan Loy, MD, MBA; and Tushar Pandey, MBA, discusses the reimbursement landscape and payer perspective on precision medicine and diagnostics and how stakeholders assess value.
Gordon Kuntz; Bryan Loy, MD, MBA; and Tushar Pandey, MBA, discusses the reimbursement landscape and payer perspective on precision medicine and diagnostics and how stakeholders assess value.
Gordon Kuntz; Bryan Loy, MD,...
09/08/2022
Journal of Clinical Pathways
Ira Klein, MD, MBD
Oncology Innovations
Episode 4: Industry Standards Needed for Next-Generation Sequencing in Cancer Care
08/17/2022
Gordon Kuntz sits down with Ira Klein, MD, MBA, to discuss the need for industry standards in next-generation sequencing and comprehensive genomic profiling and how the lack of standards is impacting patients, providers, and payers.
Gordon Kuntz sits down with Ira Klein, MD, MBA, to discuss the need for industry standards in next-generation sequencing and comprehensive genomic profiling and how the lack of standards is impacting patients, providers, and payers.
Gordon Kuntz sits down with Ira...
08/17/2022
Journal of Clinical Pathways
Carole Tremonti, RN, MBA
Oncology Innovations
Episode 3: Artificial Intelligence-Driven Clinical Decision Support for Cancer Care: Where Are We Now?
08/01/2022
Gordon Kuntz sits down with Carole Tremonti, RN, MBA, of Project Ronin to discuss clinical decision support and artificial intelligence and their role in cancer care.
Gordon Kuntz sits down with Carole Tremonti, RN, MBA, of Project Ronin to discuss clinical decision support and artificial intelligence and their role in cancer care.
Gordon Kuntz sits down with...
08/01/2022
Journal of Clinical Pathways
Bo Gamble, Community Oncology Alliance
Oncology Innovations
Episode 2: ASCO-COA Oncology Medical Home Model Provides Standards for High-Quality, Evidence-Based Care
05/23/2022
Gordon Kuntz sits down with Bo Gamble of the Community Oncology Alliance to discuss the ASCO-COA Oncology Medical Home Model, which established core elements needed to deliver equitable, high-quality cancer care.
Gordon Kuntz sits down with Bo Gamble of the Community Oncology Alliance to discuss the ASCO-COA Oncology Medical Home Model, which established core elements needed to deliver equitable, high-quality cancer care.
Gordon Kuntz sits down with Bo...
05/23/2022
Journal of Clinical Pathways
OUTSPOKEN ONCOLOGY
Episode 69: Biotech and COVID-19 Journalism With Adam Feuerstein
05/03/2022
Adam Feuerstein, national biotech columnist, STAT, provides a look into the complexity of reporting on biotech and health care advancements, the shift in STAT's editorial focus to COVID-19 coverage from a science and biotech perspective, and...
Adam Feuerstein, national biotech columnist, STAT, provides a look into the complexity of reporting on biotech and health care advancements, the shift in STAT's editorial focus to COVID-19 coverage from a science and biotech perspective, and...
Adam Feuerstein, national...
05/03/2022
Journal of Clinical Pathways
OUTSPOKEN ONCOLOGY
Episode 68: Legality of COVID-19 Travel Bans and Quarantines With Michael Sinha
05/03/2022
Michael Sinha, MD, JD, MPH, dissects the legality of international and domestic travel bans from a health policy perspective, the nuances of state-level authority to enforce a lockdown, and more.
Michael Sinha, MD, JD, MPH, dissects the legality of international and domestic travel bans from a health policy perspective, the nuances of state-level authority to enforce a lockdown, and more.
Michael Sinha, MD, JD, MPH,...
05/03/2022
Journal of Clinical Pathways
OUTSPOKEN ONCOLOGY
Episode 67: The ER Perspective on COVID-19 With Seth Trueger
05/03/2022
Seth Trueger, MD, MPH, FACEP, shares the steps taken in an emergency room setting to prepare for an influx of patients, screening processes for patient a
Seth Trueger, MD, MPH, FACEP, shares the steps taken in an emergency room setting to prepare for an influx of patients, screening processes for patient a
Seth Trueger, MD, MPH, FACEP,...
05/03/2022
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways
Conference Coverage
Polatuzumab Vedotin Plus Bendamustine-Rituximab Cost-Effective for DLBCL
12/05/2020
12/05/2020
Journal of Clinical Pathways
Conference Coverage
ASH 59th Annual Meeting and Exposition
12/07/2017
From December 9-12, the American Society of Hematology will be hosting its Annual Meeting and Exposition in Atlanta, Georgia. The meeting will provide an opportunity to review thousands of scientific abstracts...
From December 9-12, the American Society of Hematology will be hosting its Annual Meeting and Exposition in Atlanta, Georgia. The meeting will provide an opportunity to review thousands of scientific abstracts...
From...
12/07/2017
Journal of Clinical Pathways
Conference Coverage
58th American Society of Hematology (ASH) Annual Meeting & Exposition
12/13/2016
JCP Editors
Founded in 1958, the American Society of Hematology (ASH) is considered the premier professional society for physicians and scientists specializing in benign and malignant blood disorders. The organization is...
Founded in 1958, the American Society of Hematology (ASH) is considered the premier professional society for physicians and scientists specializing in benign and malignant blood disorders. The organization is...
...
12/13/2016
Journal of Clinical Pathways
Conference Coverage
2015 American Society of Hematology Annual Meeting & Exposition
02/16/2016
JCP Editors
In April of 1958, the American Society of Hematology (ASH) was formed in Atlantic City, NJ, when 300 hematologists gathered to share their insights regarding blood diseases. Today, ASH is one of the world’s largest...
In April of 1958, the American Society of Hematology (ASH) was formed in Atlantic City, NJ, when 300 hematologists gathered to share their insights regarding blood diseases. Today, ASH is one of the world’s largest...
In...
02/16/2016
Journal of Clinical Pathways
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Conference Coverage
Cybersecurity, Drug Shortages, and PBMs: Legislative Updates Impacting Oncology
04/12/2024

Grace Taylor

Grace Taylor
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry...
04/12/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement